Results of studies investigating endovascular therapy versus best medical management
| Year | Author | IVT in EVT arm | EVT mRS≤1 | EVT mRS≤2 | NIHSS shift with EVT | sICH | aICH | |||||
| aOR | P | aOR | P | Shift | P | EVT % | BMM % | EVT % | BMM % | |||
| 2014 | Urra et al4 | 47% | NS | NS | NS | NS | – | – | 11.8* | 0* | – | – |
| 2018 | Haussen et al5 | 31% | – | – | −21% | <0.01 | −3.74 | 0.016 | 6.7 | 0 | – | – |
| 2018 | Nagel et al6 | 51% | NS | NS | 3.1 | NR* | – | – | 5.2 | 2.6 | – | – |
| 2020 | *Goyal et al3 | 54% | 0.72 | 0.47 | 0.73 | 0.64 | – | – | 4.4 | 0.9 | 22* | 3* |
| 2017 | Haussen et al7 | 60% | – | – | – | – | −2.5 | 0.01 | 0 | 0 | – | – |
| 2018 | Sarraj et al8 | 31% | 1.3 | 0.47 | 0.9 | 0.77 | – | – | 5.8* | 0* | 5.3 | 10 |
| 2020 | Saito et al9 | 9.1% | NS | NS | 1.65 | 0.25 | – | – | NS | NS | NS | NS |
| 2020 | Wolman et al10 | 35% | – | – | – | – | −0.8 | 0.62 | NS | NS | 35* | 10* |
| 2017 | Dargazanli et al11 | 61% | 1.15 | NS | NS | NS | – | – | NS | NS | 16.5* | 6.1* |
| 2019 | *Shang et al12 | 29% | NS | NS | 3.2 | 0.008 | – | – | 10* | 2* | – | – |
– Analysis not performed.
*Statistically significant (p<0.05) but numbers either not reported or bivariate comparisons.
aICH, any intracranial hemorrhage or in some cases asymptomatic; aOR, adjusted OR without imputation; EVT, endovascular therapy; IVT, intravascular thrombolysis; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NR, not reported value; NS, not significant with specific number not reported; sICH, symptomatic intracranial hemorrhage.